Palisade Bio, Inc. SEC filings PALI
Palisade Bio, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Nov 16, 2011. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 10, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 21, 2026 | — |
| CORRESP | Letter to the SEC | May 19, 2026 | — |
| UPLOAD | Letter from the SEC | May 19, 2026 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| EFFECT | Filing | Aug 28, 2025 | — |
| CORRESP | Letter to the SEC | Aug 26, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 21, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2025 | — |
| DRS | Filing | Jul 3, 2025 | — |
| RW | Filing | Jun 12, 2025 | — |
| DRS | Filing | May 5, 2025 | — |
| EFFECT | Filing | Dec 16, 2024 | — |
| EFFECT | Filing | Dec 12, 2024 | — |
| CORRESP | Letter to the SEC | Dec 12, 2024 | — |
| CORRESP | Letter to the SEC | Dec 12, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| CORRESP | Letter to the SEC | Dec 10, 2024 | — |
| CORRESP | Letter to the SEC | Dec 10, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 4, 2024 | — |
| EFFECT | Filing | May 17, 2024 | — |
| CORRESP | Letter to the SEC | May 15, 2024 | — |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| D | Filing | May 10, 2024 | — |
| EFFECT | Filing | Apr 5, 2024 | — |
| CORRESP | Letter to the SEC | Apr 3, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2024 | — |
| D | Filing | Feb 13, 2024 | — |
| RW | Filing | Jan 26, 2024 | — |
| EFFECT | Filing | Apr 27, 2023 | — |
| CORRESP | Letter to the SEC | Apr 27, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2023 | — |
| D | Filing | Apr 10, 2023 | — |
| EFFECT | Filing | Jan 24, 2023 | — |
| CORRESP | Letter to the SEC | Jan 20, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2023 | — |
| D | Filing | Jan 19, 2023 | — |
| POS EX | Filing | Aug 22, 2022 | — |
| POS462B | Filing | Aug 22, 2022 | — |
| POS EX | Filing | Aug 12, 2022 | — |
| EFFECT | Filing | Aug 11, 2022 | — |
| CORRESP | Letter to the SEC | Aug 9, 2022 | — |
| CORRESP | Letter to the SEC | Aug 9, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2022 | — |
| EFFECT | Filing | Jun 23, 2022 | — |
| CORRESP | Letter to the SEC | Jun 21, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2022 | — |
| D | Filing | May 20, 2022 | — |
| EFFECT | Filing | Apr 26, 2022 | — |
| EFFECT | Filing | Apr 26, 2022 | — |
| CORRESP | Letter to the SEC | Apr 22, 2022 | — |
| CORRESP | Letter to the SEC | Apr 22, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 24, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 24, 2022 | — |
| EFFECT | Filing | Dec 8, 2021 | — |
| CORRESP | Letter to the SEC | Dec 3, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 2, 2021 | — |
| CORRESP | Letter to the SEC | Nov 18, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 8, 2021 | — |
| NT 10-Q | Filing | Aug 16, 2021 | Jun 30, 2021 |
| EFFECT | Filing | Aug 10, 2021 | — |
| CORRESP | Letter to the SEC | Aug 6, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2021 | — |
| 425 | Form 425 | Apr 20, 2021 | — |
| 425 | Filing | Apr 19, 2021 | — |
| 425 | Filing | Apr 19, 2021 | — |
| 425 | Filing | Apr 14, 2021 | — |
| 425 | Filing | Apr 13, 2021 | — |
| 425 | Form 425 | Apr 12, 2021 | — |
| 425 | Form 425 | Apr 12, 2021 | — |
| 425 | Filing | Apr 5, 2021 | — |
| 425 | Filing | Apr 2, 2021 | — |
| 425 | Filing | Mar 30, 2021 | — |
| 425 | Form 425 | Mar 29, 2021 | — |
| 425 | Filing | Mar 24, 2021 | — |
| 425 | Form 8-k | Mar 18, 2021 | — |
| 425 | Filing | Mar 18, 2021 | — |
| 425 | Filing | Mar 17, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 22, 2021 | — |
| EFFECT | Filing | Feb 11, 2021 | — |
| CORRESP | Letter to the SEC | Feb 10, 2021 | — |
| CORRESP | Letter to the SEC | Feb 9, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2021 | — |
| CORRESP | Letter to the SEC | Jan 26, 2021 | — |
| 425 | Filing | Jan 25, 2021 | — |
| 425 | Filing | Jan 20, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2021 | — |
| 425 | Filing | Jan 13, 2021 | — |
| SEC STAFF LETTER | Filing | Jan 8, 2021 | — |
| 425 | Filing | Jan 8, 2021 | — |
| 425 | Form 8-k | Dec 21, 2020 | — |
| 425 | Filing | Dec 17, 2020 | — |
| 425 | Filing | Dec 17, 2020 | — |
| EFFECT | Filing | Sep 23, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2020 | — |
| CORRESP | Letter to the SEC | Sep 22, 2020 | — |
| EFFECT | Filing | Mar 31, 2020 | — |
| CORRESP | Letter to the SEC | Mar 30, 2020 | — |
| CORRESP | Letter to the SEC | Mar 27, 2020 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2020 | — |
| D | Filing | Jan 28, 2020 | — |
| EFFECT | Filing | Jul 25, 2019 | — |
| CORRESP | Letter to the SEC | Jul 25, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 27, 2019 | — |
| EFFECT | Filing | Jul 18, 2017 | — |
| CORRESP | Letter to the SEC | Jul 14, 2017 | — |
| EFFECT | Filing | Jun 23, 2017 | — |
| CORRESP | Letter to the SEC | Jun 21, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2017 | — |
| D | Filing | May 31, 2017 | — |
| D | Filing | Dec 19, 2016 | — |
| NT 10-Q | Form nt 10-q | Aug 9, 2016 | Jun 30, 2016 |
| D | Filing | May 23, 2016 | — |
| 25 | Form 25 | Jul 10, 2015 | — |
| CERTNAS | Auto-generated paper document | Jul 9, 2015 | — |
| 8-A12B | Filing | Jul 1, 2015 | — |
| D/A | Filing | Dec 4, 2014 | — |
| D | Filing | Oct 31, 2014 | — |
| EFFECT | Filing | Jun 19, 2014 | — |
| EFFECT | Filing | Sep 13, 2013 | — |
| EFFECT | Filing | Jun 4, 2013 | — |
| D | Filing | Apr 10, 2013 | — |
| DEFR14A | Filing | May 11, 2012 | — |
| NT 10-K | Notice under rule 12b25 | Mar 15, 2012 | Dec 31, 2011 |
Showing 129 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PALI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carlsbad, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1357459
- Former names
- PALISADE BIO, INC. (until Oct 30, 2026); Seneca Biopharma, Inc. (until Apr 26, 2021); Neuralstem, Inc. (until Jan 23, 2020)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.